![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 42, 30001-30007, October 15, 1999
/
), and Human apoE Transgenic
Mice*
§¶
,
§**
¶,
§,
§,
From the
Center for the Study of Nervous System
Injury and the Departments of § Neurology, ** Molecular
Biology, and 
Pharmacology, Washington
University School of Medicine, St. Louis, Missouri 63110 and the
§§ Department of Pathology, University of
Chicago, Chicago, Illinois 60637
| |
ABSTRACT |
|---|
|
|
|---|
Composition of central nervous system
lipoproteins affects the metabolism of lipoprotein constituents within
the brain. The The composition and type of lipoproteins present in the brain have
implications not only for lipid delivery but also for the transport of
apolipoprotein (apo)1 and
other lipoprotein constituents within the central nervous system (CNS).
Glia, in particular astrocytes, are the primary cell type in the CNS
that synthesize apoE (1, 2), whereas apoJ is expressed by astrocytes
and neurons (3-5). We have previously observed that primary rat
astrocytes secrete discoidal particles the size of large plasma high
density lipoproteins (HDLs) that contain apoE and apoJ (6). As a ligand
for lipoprotein receptors, apoE helps to regulate plasma lipid and
cholesterol metabolism. This process may also be operating in the
parenchyma of the brain, as neural cells express a variety of receptors
in the low density lipoprotein receptor family (7-10). The role of
apoJ in lipid transport in both the periphery and within the CNS is
less clear, and gp330 (megalin), the only known receptor for mammalian
apoJ (11), appears to be expressed only by ependymal and endothelial cells in the brain (12, 13). Thus, lipoprotein secretion by isolated
glial cells may provide a system in which to further dissect the role
of apoE and apoJ in lipoprotein synthesis, secretion and function in
the brain.
In terms of function, several lines of evidence suggest that apoE and
apoJ may be involved in neural homeostasis beyond their capacity to
transport lipid. Both apoE and apoJ increase in response to different
brain insults (3, 14-16). In addition, apoE and apoJ may play a role
in the pathogenesis of Alzheimer's disease (AD), as both proteins
appear to interact with amyloid- The functional activity of apoE is affected by its conformation, and
the conformation of apoE is largely determined by the size,
composition, and type (disc versus sphere) of the particle with which it is associated. For example, the type of particle and
ratio of apoE to lipid determine the affinity of apoE for specific
receptors (38, 39). Therefore, we have characterized the particles
secreted by primary astrocytes as an initial step toward understanding
the function of lipoproteins unique to the CNS. Astrocytes were
cultured from wild type, apoE ( Animals--
Transgenic mice expressing human apoE3
(line 37) or apoE4 (line 1) by astrocytes in the brain in
the absence of mouse apoE (apoE ( Primary Astrocyte Cultures--
Primary cultures of forebrain
astrocytes (>95% pure) were prepared from individual neonatal (1-2
day old) mice and grown to confluency (10-14 days) in T75 flasks as
described (41). Growth medium consisted of Dulbecco's modified
Eagle's medium (Life Technologies, Inc.) containing 10% fetal bovine
serum (Hyclone, Logan, UT), 10% horse serum (Hyclone), penicillin (100 units/ml), streptomycin (100 µg/ml), and epidermal growth factor (10 ng/ml; Sigma). Once confluent, medium was removed, cells were washed
two times with sterile phosphate-buffered saline, and cultures were
incubated in 5 ml of serum-free Dulbecco's modified Eagle's
medium/Ham's F-12 (1:1) medium containing N2 supplement (Life
Technologies, Inc.) for an additional 72 h. Conditioned medium was
removed, clarified by centrifugation at ~800 × g for
5 min, and stored at 4 °C until it was analyzed. ApoE levels in
medium samples from individual cultures were quantified by Western blot
or ELISA as described below. Concentrations ranged from ~5-10 µg
of apoE/ml of unconcentrated medium.
Fractionation--
Astrocyte-conditioned medium (ACM) containing
wild type mouse apoE, no apoE (apoE ( Lipid Analysis--
Phospholipid (PL) (Wako; Richmond, VA),
total cholesterol (TC) (Roche Molecular Biochemicals), free cholesterol
(Wako), and triglyceride (TG) (Roche Molecular Biochemicals) were
measured enzymatically using commercially available kits. Cholesteryl
ester measures were determined by subtracting the free cholesterol
value from the TC value. For compositional analyses, group differences were analyzed by one-way analysis of variance followed by Bonferroni t tests.
Western Blot--
For SDS-polyacrylamide gel electrophoresis
(SDS-PAGE), samples containing 2× Laemmli buffer were boiled for 5 min
and electrophoresed on a 10-20% SDS-tricine gel. Proteins were
transferred to Immobilon-P membranes (Millipore) and probed with rabbit
antisera to rat or human apoE (1:5000) (6) and sheep antisera to rat
apoJ (1:1000; Quidel, San Diego, CA). Antisera to rat apoE cross-reacts
with mouse apoE. Immunoreactivity was visualized with enhanced
chemiluminescence (ECL, Amersham Pharmacia Biotech). Quantitation of
apoE expression in unconcentrated ACM samples was determined by
comparison to recombinant human apoE standards (42). For analysis of
relative immunostaining intensity between fractionated samples, blots
were quantitated by densitometry and comparison to apoE standards
purified from mouse or human plasma.
Electron Microscopy--
A concentrated aliquot (0.5 mg of
protein/ml) from pooled ACM fractions (~36-46) was placed on a
carbon-coated electron microscopy grid and negatively stained with 2%
phosphotungstic acid according to established procedures (43).
Particles were examined with a Phillips CM10 electron microscope.
Nondenaturing Gradient Gel Electrophoresis--
Samples of
unconcentrated ACM were electrophoresed on a nondenaturing 4-25%
polyacrylamide gradient gel as described (37), transferred to
nitrocellulose membrane, and probed with antibodies to human apoE
(1:5000; Calbiochem, La Jolla, CA) or rat apoJ (1:1000; Quidel).
Immunoreactivity was visualized with enhanced chemiluminescence.
ApoE ELISA--
Sandwich ELISA for human apoE was performed as
described (44), except that the coating antibody was rabbit antisera
raised against recombinant human apoE (42), and the detection antibody was a mouse monoclonal antibody (WU E-4) raised against human apoE
(45). Each antibody recognizes both apoE3 and apoE4.
Nondenaturing Immunoprecipitation--
One-milliliter samples of
unconcentrated ACM from apoE3 and apoE4
transgenic mice were precipitated with rabbit anti-apoE IgG (100 µg)
(42) or nonimmune rabbit IgG (100 µg) in the absence of SDS (46).
Equal volumes (30 µl) of medium samples before immunoprecipitation
(IP) and the supernatant after IP were subjected to SDS-PAGE (12.5%
acrylamide), transferred to nitrocellulose membrane, and probed with
antibodies to human apoE or rat apoJ, as described above.
Gel filtration chromatography was used to separate and isolate
astrocyte lipoproteins. In contrast to density centrifugation, this
technique has been shown to preserve the protein composition of
lipoproteins during the process of fractionation (6, 47). ACM from mice
expressing wild type (WT) mouse apoE, no apoE
(
4 allele of apolipoprotein E (apoE) is a
risk factor for Alzheimer's disease via an unknown mechanism(s). As
glia are the primary central nervous system cell type that synthesize
apoE, we characterized lipoproteins secreted by astrocytes from wild
type (WT), apoE (
/
), and apoE transgenic
mice expressing human apoE3 or apoE4 in a mouse
apoE (
/
) background. Nondenaturing size exclusion chromatography demonstrates that WT, apoE3, and apoE4 astrocytes secrete particles the size of plasma high density lipoprotein (HDL)
composed of phospholipid, free cholesterol, and protein, primarily apoE
and apoJ. However, the lipid:apoE ratio of particles containing human
apoE is significantly lower than WT. ApoE localizes across HDL-like
particle sizes. ApoJ localizes to the smallest HDL-like particles.
ApoE (
/
) astrocytes secrete little phospholipid or free
cholesterol despite comparable apoJ expression, suggesting that apoE is
required for normal secretion of astrocyte lipoproteins. Further,
particles were not detected in apoE (
/
) samples by electron microscopy. Nondenaturing immunoprecipitation experiments indicate that apoE and apoJ reside predominantly on distinct particles. These studies suggest that apoE expression influences the unique structure of astrocyte lipoproteins, a process further modified by apoE species.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
(A
), the primary component of
senile and cerebrovascular plaques in the AD brain. ApoE and apoJ
immunoreactivity is localized to senile plaques (17-19). ApoE and apoJ
interact with A
to form a stable complex (20-24), alter the
aggregation of the A
peptide (25-29), and affect A
neurotoxicity
(30-34). In humans, apoE exists as three naturally occurring isoforms
(apoE2, apoE3, and apoE4), and apoE4 is a risk factor for AD
via an isoform-specific mechanism as yet unknown. One hypothesis is
that CNS lipoproteins containing apoE and/or apoJ may provide a vehicle
for clearing A
via lipoprotein receptors (22, 35-37).
/
), and apoE
transgenic mice in which human apoE3 or apoE4 is
expressed under the control of the astrocyte-specific glial fibrillary
acidic protein promoter on a mouse apoE (
/
) background.
Our data show that expression of apoE by astrocytes is required for
normal lipoprotein secretion by these cells and that apoE species
appears to influence lipoprotein composition.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
/
)) were
generated as described (40) and mated with apoE (
/
) mice
that had been backcrossed 10 times to the C57Bl/6 background (The
Jackson Laboratory, Bar Harbor, ME). Nontransgenic littermates (human
apoE-negative, mouse apoE (
/
)) and wild type mice (mouse apoE (+/+)) of the same background strain
(C57Bl/6) were used as controls. Genotype was confirmed by polymerase
chain reaction (40). For experiments investigating the effect of apoE expression on astrocyte lipoproteins, mice hemizygous for the human
apoE transgene (human apoE (+/
), mouse
apoE (
/
)) were mated with each other in order to
generate human apoE (+/
) and human apoE (+/+)
littermates. Transgenic genotype was confirmed by quantitative slot
blot analysis of tail DNA using a probe specific for the human
apoE transgene (40), as well as by test breedings.
/
)), human apoE3,
or human apoE4 was concentrated 50-fold (Centriplus-10 or
Centriprep-10; Millipore, Bedford, MA) prior to fractionation. One
milliliter of concentrated ACM was fractionated by gel filtration
chromatography using fast protein liquid chromatography with tandem
Superose 6 columns (Amersham Pharmacia Biotech) in 0.02 M
NaPO4, 0.15 M NaCl, pH 7.4, 0.03% EDTA, and
0.02% sodium azide. Seventy fractions of 400 µl each were collected
and analyzed.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
/
, null), human apoE3 (E3), or human apoE4
(E4) was fractionated, and selected fractions were analyzed by
nonreducing SDS-PAGE and Western blotting for apoE and apoJ (Fig.
1). We were unable to detect apoAI or AII
in these samples (data not shown). In all four conditions, apoJ is
detected as a ~80-kDa species, a covalently linked dimer of two
~40-kDa subunits. The elution pattern of apoJ, as well as the
magnitude of apoJ expression, did not vary across the four conditions,
suggesting that the presence of apoE does not affect apoJ secretion by
mouse astrocytes. As expected, no apoE is detected in the ACM from
apoE (
/
) animals. In WT- and E4-ACM, apoE is primarily
detected as a ~34-36-kDa monomer, as both mouse and human E4 have no
cysteine residues (Arg-112 and Arg-158). In contrast, apoE is present
as both a ~35-kDa monomer and an ~80-kDa dimer in the E3-ACM, as
human apoE3 has a cysteine at residue 112. In all the samples, apoE and
apoJ elute in fractions consistent with lipoproteins comparable in size
to plasma HDLs (~fractions 30-48, Fig. 1). The elution profiles for
E3 and E4 are similar to wild type mouse apoE (peak, ~fractions
37-41). In contrast to apoE, apoJ elution profiles are shifted
slightly to the right (peak, ~fractions 41-45), suggesting that on
average, apoJ is associated with smaller particles.

View larger version (39K):
[in a new window]
Fig. 1.
ApoE and apoJ secretion by cultured mouse
astrocytes. Samples (50 ml) of astrocyte-conditioned medium from
primary cultures of WT, apoE (
/
), apoE3, or apoE4 mice
were concentrated to 1 ml prior to fractionation via gel filtration
chromatography. Selected fractions were subjected to SDS-PAGE under
nonreducing conditions, followed by Western blot analysis for apoE
(top row) and apoJ (bottom row). At a shorter
blot exposure (data not shown), monomeric human apoE is seen as a
doublet (~34 and ~36 kDa) due to a sialylated form; a single band
is observed for mouse apoE (~38 kDa). Free, free protein;
LDL, low density lipoproteins; VLDL, very low
density lipoproteins; MW, molecular weight (in
thousands).
Consistent with the SDS-PAGE results, profiles of the distribution of
lipid (PL and TC) and apoproteins (E and J) across the size gradient
demonstrate that astrocyte lipoproteins from mice expressing
apoE are generally the size of plasma HDLs (Fig.
2). The broad distribution of lipid and
apoproteins suggests a heterogenous population of particles ranging in
size from small low density lipoprotein (~fractions 22-29) to small
HDLs (~fractions 46-50). Lipid peaks in the void volume
(~fractions 8-12) do not contain apoproteins, suggesting the
presence of large cell membrane fragments in some samples, not the
presence of large lipoproteins. In general, the PL and TC distribution
encompassed ~fractions 35-48, peaking at fraction 41 (Fig. 2,
A and B), and is consistent with the apoprotein distribution. The apoJ elution profile from the WT, null, E3, and E4
(Fig. 2C) is comparable and consistent with apoJ being associated with a particle (peak, ~fractions 39-49, Fig.
2C) slightly smaller than apoE, which peaks ~fractions
35-45 (Fig. 2D). Again, the distribution pattern of apoJ
and the amount of apoJ secreted (~1 µg/ml unconcentrated ACM) do
not appear to vary with changes in the species (mouse versus
human) or amount of apoE secreted. In addition, there is little
detectable lipid (<2 µg/ml) secreted in the absence of apoE,
indicating that apoJ-containing "particles" are likely to be very
lipid-poor. These observations suggest that apoJ, expressed at these
levels, cannot support the normal production of astrocyte lipoproteins.
To confirm that apoE is both necessary and sufficient for the secretion
of lipoproteins by cultured mouse astrocytes, we analyzed the particles
secreted by apoJ (
/
) mice (generously provided by M. Kindy, University of Kentucky, and B. Aronow and J. Harmony, University
of Cincinnati). The lipid distribution of particles secreted by
apoJ (
/
) mice are virtually identical to the WT
particles (data not shown) demonstrating that it is apoE, not apoJ,
that drives normal levels of lipoprotein secretion by cultured mouse
astrocytes.
|
By lipid profile, particles containing human E3 and E4 are comparable in size to particles containing mouse apoE (peak ~fractions 35-48) (Fig. 2, A and B). However, particles containing E3 and E4 contain less lipid than WT particles (Fig. 2, A and B, Table I). This difference is not due to less apoE secreted by transgenic versus WT astrocytes as analysis of apoE levels demonstrates that E3 and E4 samples actually contained ~2-fold more apoE than WT samples (Fig. 2D). Thus, the endogenous mouse apoE appears to support the production of a particle that has a greater lipid:apoE ratio than human apoE.
|
To directly investigate the relationship between the amount of lipid in
astrocyte lipoproteins and the amount of apoE (by ELISA) within a given
species, we compared ACM from mice homozygous (+/+) and hemizygous
(+/
) for human E4 (Fig. 3).
Lipoproteins secreted from E4 homozygotes contain more apoE (Fig.
3A) and more TC (Fig. 3B) than those secreted
from E4 hemizygotes. These data suggest that apoE synthesis is one
predictor of the amount of lipid secreted by cultured astrocytes.
Consistent with this hypothesis, astrocytes derived from apoE (
/
)
mice produce little or no detectable lipoproteins, as assessed by
phospholipid and cholesterol analysis of size exclusion chromatography
fractions (Fig. 2, A and B). In addition,
compositional analysis of the peak fractions indicate that WT, E3, and
E4 ACM contains greater amounts of HDL-associated lipid (PL and TC)
than apoE (
/
) ACM (Table I). This analysis further
suggests that, at the very least, a subset of astrocyte particles are
discoidal in shape, as lipid analysis revealed no detectable TG or CE,
the neutral lipids that make-up the core of a spherical particles
(Table I). We have previously observed that the particles secreted by
primary rat astrocytes in culture are discoidal, in contrast to the
spherical particles found in human CSF and plasma (6). Thus, we used EM
to visualize the particles secreted by primary mouse astrocyte
cultures.
|
Electron micrographs suggest that astrocyte cultures expressing WT, E3,
or E4 contain various types of lipoprotein particles, including those
appearing as single discs, stacked discs, small spheres, and large
spheres (Fig. 4). It is likely, however,
that these nascent particles are actually predominantly discoidal in shape and appear as spheres because they adhered to the EM grid on
their sides. This assumption is based on the observation that we could
not detect any of the neutral lipids (TG or CE) that compose the core
of traditional lipoproteins in any of the mouse astrocyte samples
(Table I). However, synthesis of spherical particles in the absence of
core lipids has been described in vitro (48). The size of
mouse astrocyte particles (~11-15 nm, Table
II) is consistent with the size range of
particles from human CSF (~7-15 nm) and rat astrocyte cultures
(~9-17 nm), as well as plasma HDLs (~5-12 nm) (6). Particles from
E4 astrocytes always appear to be spherical (never as discs), and their
diameters are often larger than those from WT or E3 cultures.
Quantitation confirms that E4-ACM contains larger diameter particles on
average than WT- or E3-ACM (Table II). Consistent with analysis of mean particle diameter, frequency distributions of individual particle diameters between samples of different apoE genotype reveal a distribution in E4 samples that is shifted slightly to the right of
that for WT and E3 samples (data not shown). The astrocytes from apoE
(
/
) animals do not appear to produce particles that are detectable
by negative-staining EM (Fig. 4).
|
|
To further characterize the size and apoprotein composition of
astrocyte lipoproteins, samples from WT, apoE (
/
), E3,
and E4 were subjected to nondenaturing gradient-gel electrophoresis followed by Western blotting for apoE and apoJ (Fig.
5). Astrocyte lipoproteins containing
human E3 appear similar in size to those containing E4 or mouse apoE
(~10-17 nm) (Fig. 5A). Western blotting for apoJ also
reveals no obvious difference between particles that contain human or
mouse apoE (Fig. 5B). However, apoJ in all of these samples
is found associated with a range of particles (~7.5-12 nm) smaller
than those containing apoE (Fig. 5B). This pattern suggests
that apoE and apoJ reside predominantly on different astrocyte
lipoprotein particles, although it does not exclude the possibility
that there may be a subpopulation of particles (~10-12 nm) that
contains both apoproteins.
|
To investigate the hypothesis that apoE and apoJ reside on distinct
particles, ACM derived from E3 and E4 transgenic mice was
immunoprecipitated with an antibody specific for apoE or nonimmune IgG
as control. To preserve lipoprotein integrity, the IP was performed
under nondenaturing conditions. ACM samples before IP and supernatant
after IP were subjected to SDS-PAGE followed by Western blot analysis
for apoE and apoJ. IP with nonimmune IgG depletes little apoE or apoJ
from ACM samples. In contrast, IP with anti-apoE fully depletes samples
of apoE, whereas the majority of apoJ remains in the supernatant (Fig.
6). Results were the same for samples
containing E3 or E4 (data not shown), and IP with an antibody specific
for apoJ yielded the same conclusion (data not shown).
|
| |
DISCUSSION |
|---|
|
|
|---|
Our results suggest that apoE expression by glial cells, specifically primary cultures of mouse astrocytes, is required for the normal secretion of HDL-like lipoprotein particles by these cells. Mouse astrocyte lipoproteins appear to be composed of two separate classes of particles that contain either apoE or apoJ, a conclusion based on the results of gel filtration chromatography, native gel analysis, and nondenaturing immunoprecipitation. The apoE-containing particles contain primarily PL and free cholesterol and are ~10-15 nm in diameter as determined by size chromatography, EM, and native gels. As analyzed here, the apoJ-containing particles are ~5-10 nm in diameter, are not associated with easily detectable lipid, and are not visible by EM, suggesting a protein-rich particle. Previous studies have identified apoE and apoJ as the primary apoproteins synthesized within the brain (49, 50) Although apoAI and AII are components of CSF lipoproteins (6, 51, 52), we were unable to detect either apoAI or AII in astrocyte-conditioned medium from either rat (6) or mouse primary cultures (data not shown). Thus, it appears that synthesis of apoE drives the production of astrocyte lipoproteins. This conclusion is further supported by the observation that lipoprotein lipid secretion is proportional to the amount of apoE protein secreted by astrocytes. The contribution of lipoprotein secretion by microglial cells, which express apoE (53, 54), remains to be investigated.
Our data also suggest a heterogeneity in the size and type of particle associated with a single apoE protein sequence, as well as a difference between particles that contain mouse apoE, human apoE3, or human apoE4. The ratio of lipoprotein lipid:apoE was higher in particles containing mouse as compared with human apoE isoforms. Whether this difference reflects a species difference in apoE structure and/or conformation within particles or is somehow the result of the different promoters used to drive expression of apoE remains to be determined. At the protein level, the homology between mouse and human apoE is ~70%, including a critical substitution of threonine for arginine at residue 61 in the mouse (55). Work by Weisgraber and co-workers (56, 57) suggests that salt bridge formation involving this residue is critical for domain interactions in the human protein, an interaction that would be predicted not to occur in the mouse protein. Thus, it is reasonable to speculate that a difference in the structure of the mouse and human form of apoE could result in the secretion of nascent astrocyte lipoprotein particles with structural and composition differences. ApoE4-containing particles on average appear to be slightly larger in diameter than particles containing apoE3, and electron micrographs confirm the presence of what appear to be larger spherical particles unique to E4 samples. The preferential association of apoE4 with larger diameter particles than apoE3 may in some way be analogous to the observation that in plasma, greater quantities of 125I-apoE4 bind to very low density lipoproteins than to HDLs, whereas greater quantities of 125I-apoE2 and apoE3 bind to HDLs than to very low density lipoproteins (58). Interestingly, Guyton et al. (59) noted that CSF samples contain a novel subpopulation of large spherical particles that contain apoE, although classification by apoE isoform was not described. Although the precise significance of these observations remains unclear, it is possible that structural differences in the lipoproteins containing the three isoforms of human apoE may translate into functional differences.
ApoE-containing astrocyte particles, by virtue of interaction with the various apoE receptors expressed by both glia and neurons, may transport lipid (and other associated components) within brain parenchyma. The abundance of polar components (protein, PL, and free cholesterol) and the absence of core lipids (CE and TG) in these nascent particles makes them likely candidates for participating in the process of reverse cholesterol transport in much the same way as has been hypothesized for other interstitial fluid lipoproteins (60). In addition, the presence of apoE would allow these particles to deliver their constituents to cells through the apoE cell surface receptors known to be present on neural cells (7-10). Precise lipid trafficking is an important process in the brain as it is necessary to support the continual remodeling of the vast array of axonal and dendritic neuronal membranes. This process of membrane turnover occurs throughout the life span of the animal, accelerating under conditions of growth (during development) and following injury (traumatic or neurodegenerative disease). That apoE plays a key role in membrane maintenance is supported by the observations that apoE expression in the brain is elevated during these dynamic events (14, 61, 62), and apoE can influence neurite outgrowth in vitro (63, 64).
The proposed functions of apoJ, also known as clusterin or SP-40,40,
include lipid transport, sperm maturation, regulation of ovarian
follicle development, regulation of the complement cascade, apoptosis,
and membrane recycling (3, 65). In terms of its role as an apoprotein,
apoJ is a component of a specific class of plasma HDLs (66, 67), and a
recent in vitro study demonstrated that apoJ facilitates
lipid efflux from foam cells (68). However, the role of apoJ in
peripheral lipid metabolism remains unclear. Cultured astrocytes from
apoJ (
/
) mice offer a system to determine whether apoJ
is either necessary or sufficient for the secretion of a lipoprotein
particle. Astrocytes from these mice secrete apoE-containing
lipoprotein particles comparable to those secreted in the presence of
both apoE and apoJ (i.e. WT), demonstrating that apoJ is not
necessary for normal lipoprotein secretion by astrocytes. On the other
hand, astrocytes expressing apoJ but no apoE (i.e.
apoE (
/
)) do not secrete a particle containing sufficient lipid for detection by enzymatic analysis, nor do they secrete a particle visible by negative staining EM under the present culture conditions, suggesting that expression of apoJ is not sufficient for normal particle secretion by astrocytes. In preliminary work, however, we have detected putative small apoJ-containing particles utilizing in situ atomic force
microscopy,2 and we have
recently begun analyzing these particles. It appears clear, however,
that apoJ does not play a major role in the synthesis of lipid- and
apoE-containing astrocyte lipoproteins. Our data suggest that apoJ is
secreted as a discrete, very lipid-poor particle. Interestingly, a
subpopulation of plasma HDLs that contains apoJ has also been shown to
be very lipid-poor (69). Although apoE-containing astrocyte particles
may serve as ligands for neural apoE receptors, such a function for
apoJ is less obvious as gp330 (megalin), the only receptor identified
for mammalian apoJ (11), is not expressed by neurons or glia. Instead,
cells of the choroid plexus and ependyma, as well as brain capillary
endothelial cells at the blood-brain barrier (12, 13), express megalin.
This receptor distribution suggests that apoJ-containing particles may
be involved in the transport of lipids and associated components
between the brain, blood and CSF (13, 31).
Of particular relevance to understanding the etiology of AD are the
findings that apoE and apoJ co-localize to A
-containing senile
plaques in the AD brain (17-19) and that soluble A
is found complexed to apoE- and apoJ-containing lipoproteins in plasma and CSF
(20, 70, 71). To the extent that A
is complexed to either the lipid
or protein components of astrocyte lipoproteins within brain
parenchyma, lipoprotein trafficking would affect the metabolism
(deposition and/or clearance) of this pathologic peptide, thus perhaps
directly influencing AD pathogenesis itself. Recent studies suggest
apoE may specifically influence the deposition of A
in
vivo. Transgenic mice overexpressing a mutant form of the human
amyloid precursor protein (APPV717F), when
crossed with apoE (
/
) mice, had less A
deposition and no fibrillar A
that is normally seen in the brain in the presence of
mouse apoE (72). However, recent work by Holtzman et al. (37) demonstrated that when
APPV717F/apoE (
/
) mice were
crossed with transgenic mice expressing human apoE by astrocytes within
the brain, both apoE3 and E4 suppressed early A
deposition (37).
Thus, compositional and/or structural differences in astrocyte
lipoproteins containing the different forms of apoE may differentially
affect A
deposition. Our data suggesting differences in the
composition and size of isolated astrocyte particles containing mouse
apoE, human apoE3, or human apoE4 is consistent with such a
possibility. In addition, our observation that apoE and apoJ reside on
predominantly distinct astrocyte particles suggests that these two
populations may also subserve different functions. Further
investigation will be necessary to understand the mechanism by which
the various types of CNS lipoproteins influence both A
deposition
and clearance.
| |
FOOTNOTES |
|---|
* This study was supported by National Institutes of Health Grants AG13956 (to D. M. H), AG00861-01, and AG05681-16 (to A. M. F.); American Health Assistance Foundation Grant ADR-97006 (to C. A. R.); a grant from the University of Missouri Alzheimer's Disease and Related Disorders Program (to A. M. F.); a grant from the Ruth K. Broad Biomedical Research Foundation (to D. M. H.); and Alzheimer's Association Grants RG3-96-026 (to D. M. H) and RGI-96-053 (to C. A. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ These authors contributed equally to this work.
To whom correspondence should be addressed: Dept. of
Neurology, Box 8111, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110. Tel.: 314-747-0286; Fax:
314-362-9462; E-mail: fagana@neuro.wustl.edu.
2 T. Kowalewski, A. Fagan, and D. Holtzman, unpublished observations.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
apo, apolipoprotein;
A
, amyloid-
;
ACM, astrocyte-conditioned medium;
AD, Alzheimer's
disease;
CE, cholesteryl esters;
CNS, central nervous system;
CSF, cerebrospinal fluid;
E3, apolipoprotein E3;
E4, apolipoprotein E4;
ELISA, enzyme-linked immunosorbent assay;
EM, electron microscopy;
HDL, high density lipoprotein;
IP, immunoprecipitation;
PAGE, polyacrylamide
gel electrophoresis;
PL, phospholipid;
TC, total cholesterol;
TG, triglyceride;
WT, wild type.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Boyles, J. K., Pitas, R. E., Wilson, E., Mahley, R. W., and Taylor, J. M. (1985) J. Clin. Invest. 76, 1501-1513 |
| 2. | Pitas, R. E., Boyles, J. K., Lee, S. H., Foss, D., and Mahley, R. W. (1987) Biochim. Biophys. Acta 917, 148-161[Medline] [Order article via Infotrieve] |
| 3. | May, P. C., and Finch, C. E. (1992) Trends Neurol. Sci. 15, 391-396[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Aronow, B. J.,
Lund, S. D.,
Brown, T. L.,
Harmony, J. A. K.,
and Witte, D. P.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
725-729 |
| 5. | Pasinetti, G. M., Johnson, S., Oda, T., Rozovsky, I., and Finch, C. E. (1994) J. Comp. Neurol. 339, 387-400[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | LaDu, M. J., Gilligan, S. M., Lukens, S. R., Cabana, V. G., Reardon, C. A., Van Eldik, L. J., and Holtzman, D. M. (1998) J. Neurochem. 70, 2070-2081[Medline] [Order article via Infotrieve] |
| 7. | Krieger, M., and Herz, J. (1994) Annu. Rev. Biochem. 63, 601-637[Medline] [Order article via Infotrieve] |
| 8. | Christie, R. H., Chung, H., Rebeck, G. W., Strickland, D., and Hyman, B. T. (1996) J. Neuropathol. Exp. Neurol. 55, 491-498[Medline] [Order article via Infotrieve] |
| 9. |
Kim, D. H.,
Iijima, H.,
Goto, K.,
Sakai, J.,
Ishii, H.,
Kim, H. J.,
Suzuki, H.,
Kondo, H.,
Saeki, S.,
and Yamamoto, T.
(1996)
J. Biol. Chem.
271,
8373-8380 |
| 10. |
Novak, S.,
Hiesberger, T.,
Schneider, W. J.,
and Nimpf, J.
(1996)
J. Biol. Chem.
271,
11732-11736 |
| 11. |
Kounnas, M. Z.,
Loukinova, E. B.,
Stefansson, S.,
Harmony, J. A.,
Brewer, B. H.,
Strickland, D. K.,
and Argraves, W. S.
(1995)
J. Biol. Chem.
270,
13070-13075 |
| 12. | Kounnas, M. Z., Haudenschild, C. C., Strickland, D. K., and Argraves, W. S. (1994) In Vivo 8, 343-351[Medline] [Order article via Infotrieve] |
| 13. |
Zlokovic, B. V.,
Martel, C. L.,
Matsubara, E.,
McComb, J. G.,
Zheng, G.,
McCluskey, R. T.,
Frangione, B.,
and Ghiso, J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
4229-4234 |
| 14. | Poirier, J., Hess, M., May, P. C., and Finch, C. E. (1991) Mol. Brain Res. 11, 97-106[Medline] [Order article via Infotrieve] |
| 15. | Pasinetti, G. M., Cheng, H. W., Morgan, T., Lampert-Etchells, M., McNeill, T. H., and Finch, C. E. (1993) Neurosci. 53, 199-211[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Schreiber, S., Tocco, G., Najm, I., and Baudry, M. (1993) Neurosci. Lett. 153, 17-20[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., and Ikeda, K. (1991) Brain Res. 541, 163-166[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Choi-Miura, N. H., Ihara, Y., Fukuchi, K., Takeda, M., Nakano, Y., Tobe, T., and Tomita, M. (1992) Acta Neuropathol. 83, 260-264[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Wisniewski, T., Ghiso, J., and Frangione, B. (1997) Neurobiol. Dis. 4, 313-328[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Ghiso, J., Matsubara, E., Koudinov, A., Choi-Miura, N. H., Tomita, M., Wisniewski, T., and Frangione, B. (1993) Biochem. J. 293, 27-30 |
| 21. |
Strittmatter, W. J.,
Weisgraber, K. H.,
Huang, D. Y.,
Dong, L.-Y.,
Salvesen, G. S.,
Pericak-Vance, M.,
Schmechel, D.,
Saunders, A. M.,
Goldgaber, D.,
and Roses, A. D.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
8098-8102 |
| 22. |
LaDu, M. J.,
Falduto, M. T.,
Manelli, A. M.,
Reardon, C. A.,
Getz, G. S.,
and Frail, D. E.
(1994)
J. Biol. Chem.
269,
23403-23406 |
| 23. |
LaDu, M. J.,
Pederson, T. M.,
Frail, D. E.,
Reardon, C. A.,
Getz, G. S.,
and Falduto, M. T.
(1995)
J. Biol. Chem.
270,
9039-9042 |
| 24. |
Matsubara, E.,
Frangione, B.,
and Ghiso, J.
(1995)
J. Biol. Chem.
270,
7563-7567 |
| 25. |
Evans, K. C.,
Berger, E. P.,
Cho, C.-G.,
Weisgraber, K. H.,
and Lansbury, P. T.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
92,
763-767 |
| 26. | Ma, J., Yee, A., Brewer, H. B., Das, S., and Potter, H. (1994) Nature 372, 92-94[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Sanan, D. A., Weisgraber, K. H., Russel, S. J., Mahley, R. W., Huang, D., Saunders, A., Schmechel, D., Wisniewksi, T., Frangione, B., Roses, B., Roses, A. D., and Strittmatter, W. J. (1994) J. Clin. Invest. 94, 860-869 |
| 28. | Castano, E. M., Prelli, F., Wisniewski, T., Golabek, A., Kumar, R. A., Soto, C., and Frangione, B. (1995) Biochem. J. 306, 599-604 |
| 29. | Oda, T., Wals, P., Osterburg, H. H., Johnson, S. A., Pasinetti, G. M., Morgan, T. M., Rozovsky, I., Stine, W. B., Snyder, S. W., Holzman, T. F., Krafft, G., and Finch, C. E. (1995) Exp. Neurol. 136, 22-31[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Oda, T., Pasinetti, G. M., Osterburg, H. H., Anderson, C., Johnson, A., and Finch, C. E. (1994) Biochem. Biophys. Res. Commun. 204, 1131-1136[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Zlokovic, B. V., Martel, C. L., Mackic, J. B., Matsubara, E., Wisniewski, T., McComb, J. G., Frangione, B., and Ghiso, J. (1994) Biochem. Biophys. Res. Commun. 205, 1431-1437[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Boggs, L. N., Fuson, K. S., Baez, M., Churgay, L., McClure, D., Becker, G., and May, P. C. (1996) J. Neurochem. 67, 1324-1327[Medline] [Order article via Infotrieve] |
| 33. | Ma, J., Brewer, H., and Potter, H. (1996) Neurobiol. Aging 17, 773-780[CrossRef][Medline] [Order article via Infotrieve] |
| 34. |
Lambert, M. P.,
Barlow, A. K.,
Chromy, B. A.,
Edwards, C.,
Freed, R.,
Liosatsos, M.,
Morgan, T. E.,
Rozovsky, I.,
Trommer, B.,
Viola, K. L.,
Wals, P.,
Zhang, C.,
Finch, C. E.,
Krafft, G. A.,
and Klein, W. L.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
6448-6453 |
| 35. | Rebeck, G. W., Reiter, J. S., Strickland, D. K., and Hyman, B. T. (1993) Neuron 11, 575-580[CrossRef][Medline] [Order article via Infotrieve] |
| 36. |
Hammad, S. M.,
Ranganathan, S.,
Loukinova, E.,
Twal, W. O.,
and Argraves, W. S.
(1997)
J. Biol. Chem.
272,
18644-18649 |
| 37. | Holtzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., and Paul, S. M. (1999) J. Clin. Invest. 103, R15-R21[Medline] [Order article via Infotrieve] |
| 38. | Innerarity, T. L., and Mahley, R. W. (1978) Biochem. 17, 1440-1447[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Innerarity, T. L., Pitas, R. E., and Mahley, R. W. (1986) Methods Enzymol. 129, 542-565[Medline] [Order article via Infotrieve] |
| 40. |
Sun, Y.,
Wu, S.,
Bu, G.,
Onifade, M. K.,
Patel, S. N.,
LaDu, M. J.,
Fagan, A. M.,
and Holtzman, D. M.
(1998)
J. Neurosci.
18,
3261-3272 |
| 41. | Rose, K., Goldberg, M. P., and Choi, D. W. (1993) in In Vitro Biological Methods: Methods in Toxicology (Tyson, C. A. , and Frazier, J. M., eds), Vol. 1A , pp. 46-60, Academic Press, Inc., San Diego |
| 42. |
Fagan, A. M.,
Bu, G.,
Sun, Y.,
Daugherty, A.,
and Holtzman, D. M.
(1996)
J. Biol. Chem.
271,
30121-30125 |
| 43. | Forte, T. M., and Nordhausen, R. W. (1986) Methods Enzymol. 128, 442-457[Medline] [Order article via Infotrieve] |
| 44. | Mobley, W. C., Woo, J. E., Edwards, R. H., Riopelle, R. J., Longo, F. M., Weskamp, G., Otten, U., Valletta, J. S., and Johnston, M. V. (1989) Neuron 3, 655-664[CrossRef][Medline] [Order article via Infotrieve] |
| 45. | Krul, E. S., Tikkanen, M. J., and Schonfeld, G. (1988) J. Lipid Res. 29, 1309-1325[Abstract] |
| 46. |
Reardon, C.,
Blachowicz, L.,
Watson, K.,
Barr, E.,
and Getz, G.
(1998)
J. Lipid Res.
39,
1372-1381 |
| 47. | Castro, G. R., and Fielding, C. J. (1984) J. Lipid Res. 25, 58-67[Abstract] |
| 48. | Nishida, H. I., Klock, D. G., Guo, Z., Jakstys, B. P., and Nishida, T. (1997) Biochim. Biophys. Acta 1349, 222-232[Medline] [Order article via Infotrieve] |
| 49. |
Newman, T. C.,
Dawson, P. A.,
Rudel, L. L.,
and Williams, D. L.
(1985)
J. Biol. Chem.
260,
2452-2457 |
| 50. | de Silva, H. V., Harmony, J. A. K., Stuart, W. D., Gil, C. M., and Robbins, J. (1990) Biochemistry 29, 5380-5389[CrossRef][Medline] [Order article via Infotrieve] |
| 51. |
Roheim, P. S.,
Carey, M.,
Forte, T.,
and Vega, G. L.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
4646-4649 |
| 52. |
Pitas, R. E.,
Boyles, J. K.,
Lee, S. H.,
Hui, D.,
and Weisgraber, K. H.
(1987)
J. Biol. Chem.
262,
14352-14360 |
| 53. | Nakai, M., Kawamata, T., Maeda, K., and Tanaka, C. (1996) Neurosci. Lett. 211, 41-44[CrossRef][Medline] [Order article via Infotrieve] |
| 54. | Stone, D. J., Rozovsky, I., Morgan, T. E., Anderson, C. P., Hajian, H., and Finch, C. E. (1997) Exp. Neurol. 143, 313-318[CrossRef][Medline] [Order article via Infotrieve] |
| 55. | Weisgraber, K. H. (1994) Adv. Protein Chem. 45, 249-302[Medline] [Order article via Infotrieve] |
| 56. |
Dong, L. M.,
Wilson, C.,
Wardell, M. R.,
Simmons, T.,
Mahley, R. W.,
Weisgraber, K. H.,
and Agund, D. A.
(1994)
J. Biol. Chem.
269,
22358-22365 |
| 57. |
Dong, L. M.,
and Weisgraber, K. H.
(1996)
J. Biol. Chem.
271,
19053-19057 |
| 58. | Weisgraber, K. H. (1990) J. Lipid Res. 31, 1503-1511[Abstract] |
| 59. | Guyton, J. R., Miller, S. R., Martin, M. E., Khan, W. A., Roses, A. D., and Strittmatter, W. J. (1998) J. Neurochem. 70, 1235-1240[Medline] [Order article via Infotrieve] |
| 60. | Sloop, C. H., Dory, L., and Roheim, P. S. (1987) J. Lipid Res. 28, 225-237[Abstract] |
| 61. |
Elshourbagy, N. A.,
Liao, W. S.,
Mahley, R. W.,
and Taylor, J. M.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
203-207 |
| 62. | Mouchel, Y., Lefrancois, T., Fages, C., and Tardy, M. (1995) Neuroreport 7, 205-208[Medline] [Order article via Infotrieve] |
| 63. |
Nathan, B. P.,
Bellosta, S.,
Sanan, D. A.,
Weisgraber, K. H.,
Mahley, R. W.,
and Pitas, R. E.
(1994)
Science
264,
850-852 |
| 64. |
Holtzman, D. M.,
Pitas, R. E.,
Kilbridge, J.,
Nathan, B.,
Mahley, R. W.,
Bu, G.,
and Schwartz, A. L.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
9480-9484 |
| 65. | Jordan-Starck, T. C., Witte, D. P., Aronow, B. J., and Harmony, J. A. K. (1992) Curr. Opin. Lipidol. 3, 75-85[CrossRef] |
| 66. | Hochstrasser, A.-C., James, R. W., Martin, B. M., Harrington, M., Hochstrasser, D., Pometta, D., and Merril, C. R. (1988) Appl. Theoret. Electroph. 1, 73-76[Medline] [Order article via Infotrieve] |
| 67. |
de Silva, H. V.,
Stuart, W. D.,
Duvic, C. R.,
Wetterau, J. R.,
Ray, M. J.,
Ferguson, D. G.,
Albers, H. W.,
Smith, W. R.,
and Harmony, J. A. K.
(1990)
J. Biol. Chem.
265,
13240-13247 |
| 68. | Gelissen, I. C., Hochgrebe, T., Wilson, M. R., Easterbrook-Smith, S. B., Jessup, W., Dean, R. T., and Brown, A. J. (1998) Biochem. J. 331, 231-237 |
| 69. |
Jenne, D. E.,
Lowin, B.,
Peitsch, M. C.,
Bottcher, A.,
Schmitz, G.,
and Tschopp, J.
(1991)
J. Biol. Chem.
266,
11030-11036 |
| 70. | Koudinov, A., Matsubara, E., Frangione, B., and Ghiso, J. (1994) Biochem. Biophys. Res. Commun. 205, 1164-1171[CrossRef][Medline] [Order article via Infotrieve] |
| 71. | Koudinov, A. R., Koudinova, N. V., Kumar, A., Beavis, R. C., and Ghiso, J. (1996) Biochem. Biophys. Res. Commun. 223, 592-597[CrossRef][Medline] [Order article via Infotrieve] |
| 72. | Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., Piccardo, P., Ghetti, B., and Paul, S. M. (1997) Nat. Genet. 17, 263-264[Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
S. Kurumada, A. Onishi, H. Imai, K. Ishii, T. Kobayashi, and S. B. Sato Stage-Specific Association of Apolipoprotein A-I and E in Developing Mouse Retina Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1815 - 1823. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Kim, A. S. Rahmanto, A. Kamili, K.-A. Rye, G. J. Guillemin, I. C. Gelissen, W. Jessup, A. F. Hill, and B. Garner Role of ABCG1 and ABCA1 in Regulation of Neuronal Cholesterol Efflux to Apolipoprotein E Discs and Suppression of Amyloid-beta Peptide Generation J. Biol. Chem., February 2, 2007; 282(5): 2851 - 2861. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Mahley, K. H. Weisgraber, and Y. Huang Inaugural Article: Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease PNAS, April 11, 2006; 103(15): 5644 - 5651. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Karten, R. B. Campenot, D. E. Vance, and J. E. Vance Expression of ABCG1, but Not ABCA1, Correlates with Cholesterol Release by Cerebellar Astroglia J. Biol. Chem., February 17, 2006; 281(7): 4049 - 4057. [Abstract] [Full Text] [PDF] |
||||
![]() |
|